Now in it’s 25th year, the PharmaTimes Marketer of the Year competition closes for entry on Friday 14th September – make sure you take advantage of this great opportunity for you and your team to compete, benchmark, learn and raise standards in pharma marketing.
US regulators have extended the review period for Roche’s application to market Tecentriq in combination with Avastin, carboplatin and paclitaxel for first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).
Teva Pharmaceutical Industries has decided not to pursue development of laquinimod, and has returned rights to the drug back to Swedish group Active Biotech.
Celltrion Healthcare is calling on the NHS to consider lowering the threshold for starting biologics in patients with rheumatoid arthritis (RA), and to put in place measures to boost patient access to such treatment.
Lord Prior of Brampton has been named as the government’s preferred new chair of NHS England, replacing Professor Sir Malcolm Grant.
Novartis is selling parts of its generics business Sandoz to Aurobindo in a deal worth at least $900 million.
The inaugural PharmaTimes Sales Awards – established to recognise and celebrate the very best sales professionals in the industry today – will close for entries on September 7.
US regulators are undertaking a priority review of MSD’s Keytruda for the treatment of adult and paediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
Horizon Pharma says it has completed enrollment in a confirmatory Phase III trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED) ahead of schedule.
New research has discovered a subset of men with prostate cancer who have specific faults in their tumours that significantly worsen their chances of survival, but could mean they are more likely to benefit from immunotherapy.
Hospitals are gearing up to offer Novartis’ ground-breaking CAR-T therapy Kymriah to children with advanced leukaemia, after the drugmaker reached a deal with NHS England over its provision.
The National Institute for Health and Care Excellence (NICE) has changed its position on NHS funding for Kyowa Kirin International’s Crysvita, now endorsing the drug’s use to treat X-linked hypophosphataemia (XLH) in children and young people with growing bones in England and Wales.
Four in five people have a heart age older than their real age, leaving them at risk of early death from cardiovascular disease, Public Health England data show.
Novo Nordisk and the University of Oxford are poised to begin ground-breaking work on therapeutic targets for type II diabetes with new research facilities set to open next week.
Hundreds of millions of pounds could be freed up for front-line care if the NHS were to cut back on its use of agency staff, according to NHS Improvement.
